{"id":"https://openalex.org/W4405501008","doi":"https://doi.org/10.5812/ijpr-153452","title":"Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran","display_name":"Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran","publication_year":2024,"publication_date":"2024-12-17","ids":{"openalex":"https://openalex.org/W4405501008","doi":"https://doi.org/10.5812/ijpr-153452","pmid":"https://pubmed.ncbi.nlm.nih.gov/40365303","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/12070311"},"language":"en","primary_location":{"id":"doi:10.5812/ijpr-153452","doi":"https://doi.org/10.5812/ijpr-153452","is_oa":true,"landing_page_url":"https://doi.org/10.5812/ijpr-153452","pdf_url":"https://brieflands.com/articles/ijpr-153452.pdf","source":{"id":"https://openalex.org/S54803862","display_name":"Iranian journal of pharmaceutical research","issn_l":"1726-6882","issn":["1726-6882","1726-6890","1735-0328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310319054","host_organization_name":"Shahid Beheshti University","host_organization_lineage":["https://openalex.org/P4310319054"],"host_organization_lineage_names":["Shahid Beheshti University"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Iranian Journal of Pharmaceutical Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://brieflands.com/articles/ijpr-153452.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025369958","display_name":"Homa Hemati","orcid":"https://orcid.org/0000-0002-8704-2144","observed_orcids":["https://orcid.org/0000-0002-8704-2144"]},"institutions":[{"id":"https://openalex.org/I70640408","display_name":"Tehran University of Medical Sciences","ror":"https://ror.org/01c4pz451","country_code":"IR","type":"education","lineage":["https://openalex.org/I70640408"]}],"countries":["IR"],"is_corresponding":false,"raw_author_name":"Homa Hemati","raw_affiliation_strings":["Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I70640408"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049455211","display_name":"Marzieh Nosrati","orcid":"https://orcid.org/0000-0001-8964-1653","observed_orcids":["https://orcid.org/0000-0001-8964-1653"]},"institutions":[{"id":"https://openalex.org/I4403928185","display_name":"Endocrinology and Metabolism Clinical Sciences Institute","ror":"https://ror.org/0430z0381","country_code":"IR","type":"facility","lineage":["https://openalex.org/I4403928185","https://openalex.org/I4403928377","https://openalex.org/I70640408"]},{"id":"https://openalex.org/I4403928333","display_name":"Personalized Medicine Research Center","ror":"https://ror.org/04690an59","country_code":"IR","type":"facility","lineage":["https://openalex.org/I4403928185","https://openalex.org/I4403928333","https://openalex.org/I4403928377","https://openalex.org/I70640408"]},{"id":"https://openalex.org/I70640408","display_name":"Tehran University of Medical Sciences","ror":"https://ror.org/01c4pz451","country_code":"IR","type":"education","lineage":["https://openalex.org/I70640408"]}],"countries":["IR"],"is_corresponding":false,"raw_author_name":"Marzieh Nosrati","raw_affiliation_strings":["Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran","Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I70640408"]},{"raw_affiliation_string":"Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I4403928185","https://openalex.org/I4403928333","https://openalex.org/I70640408"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086646553","display_name":"Meysam Seyedifar","orcid":"https://orcid.org/0000-0003-0426-1956","observed_orcids":["https://orcid.org/0000-0003-0426-1956"]},"institutions":[{"id":"https://openalex.org/I4403928282","display_name":"Pharmaceutical Management and Economics Research Center","ror":"https://ror.org/01w4ywr53","country_code":"IR","type":"facility","lineage":["https://openalex.org/I4403928282","https://openalex.org/I4403928403","https://openalex.org/I70640408"]},{"id":"https://openalex.org/I70640408","display_name":"Tehran University of Medical Sciences","ror":"https://ror.org/01c4pz451","country_code":"IR","type":"education","lineage":["https://openalex.org/I70640408"]}],"countries":["IR"],"is_corresponding":true,"raw_author_name":"Meysam Seyedifar","raw_affiliation_strings":["Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran","Pharmaceutical Management and Economic Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I70640408"]},{"raw_affiliation_string":"Pharmaceutical Management and Economic Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I4403928282","https://openalex.org/I70640408"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5086646553"],"corresponding_institution_ids":["https://openalex.org/I4403928282","https://openalex.org/I70640408"],"apc_list":null,"apc_paid":null,"fwci":0.2776,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.55501155,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"23","issue":"1","first_page":"e153452","last_page":"e153452"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9380000233650208},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9900000095367432},{"id":"https://openalex.org/keywords/cost-utility-analysis","display_name":"cost-utility analysis","score":0.8610000014305115},{"id":"https://openalex.org/keywords/budget-impact","display_name":"budget impact","score":0.7409999966621399},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.8460000157356262},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9190000295639038},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8080000281333923},{"id":"https://openalex.org/keywords/iran","display_name":"Iran","score":0.4429999887943268},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.49300000071525574},{"id":"https://openalex.org/keywords/invasive-disease-free-survival","display_name":"invasive disease-free survival","score":0.8109999895095825},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.527999997138977},{"id":"https://openalex.org/keywords/sensitivity-analysis","display_name":"sensitivity analysis","score":0.5569999814033508}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.8306518197059631},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8091568946838379},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7657003402709961},{"id":"https://openalex.org/C2778087150","wikidata":"https://www.wikidata.org/wiki/Q3997863","display_name":"Trastuzumab emtansine","level":5,"score":0.7129203081130981},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5746122598648071},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4991896152496338},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.48356911540031433},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44710618257522583},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.41619521379470825},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.08601561188697815}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.5812/ijpr-153452","doi":"https://doi.org/10.5812/ijpr-153452","is_oa":true,"landing_page_url":"https://doi.org/10.5812/ijpr-153452","pdf_url":"https://brieflands.com/articles/ijpr-153452.pdf","source":{"id":"https://openalex.org/S54803862","display_name":"Iranian journal of pharmaceutical research","issn_l":"1726-6882","issn":["1726-6882","1726-6890","1735-0328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310319054","host_organization_name":"Shahid Beheshti University","host_organization_lineage":["https://openalex.org/P4310319054"],"host_organization_lineage_names":["Shahid Beheshti University"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Iranian Journal of Pharmaceutical Research","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12070311","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12070311","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12070311/pdf/ijpr-23-1-153452.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Iran J Pharm Res","raw_type":"Text"},{"id":"pmid:40365303","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40365303","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Iranian journal of pharmaceutical research : IJPR","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.5812/ijpr-153452","doi":"https://doi.org/10.5812/ijpr-153452","is_oa":true,"landing_page_url":"https://doi.org/10.5812/ijpr-153452","pdf_url":"https://brieflands.com/articles/ijpr-153452.pdf","source":{"id":"https://openalex.org/S54803862","display_name":"Iranian journal of pharmaceutical research","issn_l":"1726-6882","issn":["1726-6882","1726-6890","1735-0328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310319054","host_organization_name":"Shahid Beheshti University","host_organization_lineage":["https://openalex.org/P4310319054"],"host_organization_lineage_names":["Shahid Beheshti University"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Iranian Journal of Pharmaceutical Research","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4405501008.pdf","grobid_xml":"https://content.openalex.org/works/W4405501008.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1994561005","https://openalex.org/W2010030230","https://openalex.org/W2017628547","https://openalex.org/W2020677481","https://openalex.org/W2042960078","https://openalex.org/W2063841790","https://openalex.org/W2089190823","https://openalex.org/W2101860994","https://openalex.org/W2121314053","https://openalex.org/W2128473443","https://openalex.org/W2140502073","https://openalex.org/W2281842333","https://openalex.org/W2292132270","https://openalex.org/W2414298749","https://openalex.org/W2512440162","https://openalex.org/W2536868151","https://openalex.org/W2578338309","https://openalex.org/W2767479677","https://openalex.org/W2902218997","https://openalex.org/W2912923142","https://openalex.org/W2917837889","https://openalex.org/W2923062528","https://openalex.org/W2958119318","https://openalex.org/W3013769138","https://openalex.org/W3020186439","https://openalex.org/W3094290388","https://openalex.org/W3116148769","https://openalex.org/W3128646645","https://openalex.org/W3133749166","https://openalex.org/W3161375768","https://openalex.org/W3193347331","https://openalex.org/W4285135693","https://openalex.org/W4307021407"],"related_works":["https://openalex.org/W4410420824","https://openalex.org/W3113189398","https://openalex.org/W3161375768","https://openalex.org/W7203637360","https://openalex.org/W3111710014","https://openalex.org/W4388653253","https://openalex.org/W2134169490","https://openalex.org/W4408376226","https://openalex.org/W3152541802","https://openalex.org/W4311333026"],"abstract_inverted_index":{"Background:":[0],"Breast":[1],"cancer":[2,11,23,38,54,123,339],"is":[3,17,24,48,326],"one":[4],"of":[5,10,36,68,88,95,143,178,192,205,229,239,259,274,286,334],"the":[6,66,81,85,93,125,203,206,252,257,263,272,294,303,332],"most":[7],"common":[8],"types":[9],"in":[12,19,72,137,217,340],"women,":[13],"and":[14,26,70,83,147,156,172,189,196,261,269,271],"its":[15],"incidence":[16,67],"increasing":[18],"Iran.":[20,341],"HER-2-positive":[21,98,121,337],"breast":[22,37,73,99,122,338],"invasive":[25,97,120,276,336],"often":[27],"associated":[28],"with":[29,33,105,118,134,214,225],"poorer":[30],"outcomes.":[31],"Patients":[32],"this":[34],"type":[35],"can":[39],"develop":[40],"resistance":[41,56],"to":[42,52,57,64,79,201,256,317],"medications":[43],"like":[44],"trastuzumab.":[45,58,318],"Trastuzumab-emtansine":[46],"(TDM1)":[47],"a":[49,106,130,218,311],"medication":[50],"developed":[51],"reduce":[53],"cell":[55],"The":[59,127,184,209,297],"TDM1":[60,89,193,215,260,308,321],"has":[61],"been":[62],"shown":[63],"decrease":[65],"death":[69],"recurrence":[71],"cancer.":[74,100],"Objectives:":[75],"This":[76,231],"study":[77,128],"aimed":[78],"evaluate":[80],"cost-utility":[82],"calculate":[84],"budget":[86,190,298,305],"impact":[87,191,299],"versus":[90],"trastuzumab":[91,330],"for":[92,145,149,182,266,307,331],"treatment":[94,213,309,333],"residual":[96,119,335],"Methods:":[101],"A":[102],"Markov":[103],"model":[104,210,253],"lifetime":[107],"horizon":[108],"was":[109,180,232,254,314],"developed,":[110],"incorporating":[111],"four":[112],"health":[113],"states.":[114],"Women":[115],"aged":[116],"45":[117],"entered":[124],"model.":[126,207],"adopted":[129],"healthcare":[131],"system":[132],"perspective,":[133],"costs":[135,146,258],"reported":[136],"2021":[138],"US":[139],"dollars.":[140],"Discount":[141],"rates":[142,265],"7%":[144],"3%":[148],"utility":[150,267],"values":[151,155,268],"were":[152,159,165,194,199],"applied.":[153],"Utility":[154],"transition":[157],"probabilities":[158],"derived":[160],"from":[161],"published":[162],"literature.":[163],"Costs":[164],"estimated":[166],"based":[167],"on":[168],"guidelines,":[169],"expert":[170],"opinions,":[171],"Iranian":[173],"tariffs.":[174],"Iran's":[175,236,290],"pharmacoeconomic":[176,237,291],"threshold":[177,238],"1085$":[179,240],"used":[181],"comparison.":[183],"incremental":[185],"cost-effectiveness":[186],"ratio":[187],"(ICER)":[188],"calculated,":[195],"sensitivity":[197,248,281],"analyses":[198],"conducted":[200],"assess":[202],"robustness":[204],"Results:":[208],"indicated":[211],"that":[212,251,284,302],"resulted":[216],"1.59":[219],"quality-adjusted":[220],"life":[221],"year":[222],"(QALY)":[223],"increase,":[224],"an":[226],"additional":[227,304],"cost":[228],"1408$.":[230],"deemed":[233],"cost-effective,":[234],"considering":[235],"(calculated":[241],"ICER:":[242],"886$":[243],"per":[244],"QALY":[245],"gained).":[246],"One-way":[247],"analysis":[249,282,300],"revealed":[250,301],"sensitive":[255],"trastuzumab,":[262],"discount":[264],"costs,":[270,324],"probability":[273],"achieving":[275],"disease-free":[277],"survival":[278],"(IDFS).":[279],"Probabilistic":[280],"showed":[283],"59.61%":[285],"simulations":[287],"fell":[288],"below":[289],"threshold,":[292],"supporting":[293],"model's":[295],"robustness.":[296],"required":[306],"over":[310],"three-year":[312],"period":[313],"1,120,546$":[315],"compared":[316],"Conclusions:":[319],"Although":[320],"imposes":[322],"higher":[323],"it":[325],"more":[327],"cost-effective":[328],"than":[329]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2024-12-18T00:00:00"}